It is important to emphasize that our findings do not contradict with the potential of B2AR agonists to reduce monocyte activation and pro-inflammatory responses in the kidneys and heart during obesity and type-2 diabetes, as previously reported [57]. This evidence concerns the gene ADRB2 and obesity due to melanocortin 4 receptor deficiency.